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ABSTRACT 
 
 
Technology Readiness Level (TRL) is widely used as a measure of technology maturity. 
However, TRL is not necessarily a good indicator of commercial readiness. In the renewable 
energy sector a Commercial Readiness Index (CRI) is used where only a technology with a high 
TRL qualifies for commercial readiness. Similarly TRL is used to measure the maturity  of 
Additive Manufacturing (AM) technologies. This research proposes a  Commercial  Readiness 
Index (CRI) for Additive Manufacturing. A case-study on maxillofacial Ti6Al4V implants 
manufactured with AM is referred to. 
Page 39  
1. INTRODUCTION 
 
Previous research [1] on a step-by-step risk assessment of the process of manufacturing a 
successful maxillofacial implant showed to be theoretically unfeasible due to the risks being 
too high. In order to move from theoretical feasibility to real feasibility a mechanism to 
analyse the high risks needs to be developed. 
 
The following case study is used; a maxillofacial implant manufacturing process. The Centre 
of Rapid Prototyping and Manufacturing (CRPM) [2] has been accredited to manufacture 
implants according to ISO13485. The commercialisation of this manufacturing process is 
currently in the ramp-up phase. The commercial sustainability of the manufacturing process 
still needs to be verified. This research uses as a base the Commercial Readiness Index (CRI) 
assessment, created by the Australian Renewable Energy Agency (ARENA) [3] [4].  The ARENA 
CRI is modified to apply to AM by using analysis and synthesis approach. The CRI is divided into 
several independent indicators assessing various commercial aspects and then combined into 
a single commercial index. 
 
Therefore the CRI is compiled from commercial indicators including; Regulatory Environment, 
Stakeholder Acceptance, Clinical Performance, Technical Performance, Financial 
Performance - Cost, Financial Proposition -Revenue, Industry Supply Chain and Skills, Market 
Opportunities and Company Maturity.  A diverse group of 15 experts assisted   in defining 
maturity in each of the commercial indicators. The compiled results are presented. The value 
of this research lies in the ability for investors to now assess the commercial viability of AM. 
AM is considered a disruptive and emerging technology designated to replace conventional 
manufacturing processes. 
 
2. METHODOLOGY 
 
The research has started by interviewing seventeen experts on their view and opinion on 
commercial readiness. These experts were chosen based on their knowledge within specific 
industries. The professional environments of these experts include: Associate Professors from 
different South-African Universities, investment managers, senior directors of innovative 
companies, venture capitalists, executive managers and mechanical engineers. These experts 
are versed in: strategic decision making; experience  in  standards development for materials; 
paediatric applications; managing  product-to-market endeavours; maxillofacial 
reconstruction; venture capitalism; commercial incubator activities; innovation processes ; 
aerospace product development ; enterprise engineering; regulatory and conformance 
quality; logistics and supply chain and systems integration. 
Their opinions contributed to defining the CRI indicators for AM. Using the TRL, introduced by 
NASA in 1970[5], each of the technologies are evaluated in terms of their maturity. The 
individual TRL’s will be added in the value chain in order to calculate the CRI 
 
2.1  Objectives 
1. Define CRI for AM based on CRI for renewable energy by process of expert opinion 
2. To define a framework against which the commercial maturity of processes using   
AM technology can be measured 
3. To use a case study to confirm the framework 
 
 
3. LITERATURE ANALYSIS REVIEW 
 
3.1 Additive Manufacturing technologies within medicine 
At the start of this research, a better understanding of AM in general was needed. Additive 
Manufacturing products within the medical industry are of high value and small physical 
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volume, custom-designed within the AM technology. These products continue to deliver 
innovative solutions for customer needs [6]. 
AM medical devices can improve the manufacturing of the product and the physical fit to the 
patient, supporting the medical device industry which focuses on enhanced customisation. 
The alignment between medical device and AM is strong due to the demand for low-volume, 
high-customised products with life dependent outcomes. This is exactly the case for the 
maxillofacial implant. 
3.1.1 Maxillofacial implant 
 
Figure 1: Maxillofacial implant [2] 
 
The CRPM has been successful in manufacturing and implanting this implant, shown in   Figure 
1. The CRPM is an institute of the Central University of Technology (CUT). 
 
3.1.2 AM research funding 
The development of AM technologies in South Africa has been through provisional and upfront 
grants [7]. Grants from the government can be useful in assisting companies with funding for 
their projects. The introduction of new technologies into existing markets face difficulties in 
the commercialisation process [3]. 
 
3.2 Defining key terms 
3.2.1 The manufacturing process chain 
The manufacturing process chain is the specific part within the production we are interested 
in to calculate the TRL. First we need to discuss the different types of TRLs. 
The technology that you buy from the supplier is integrated into your manufacturing process. 
That technology then has a new TRL within your process. The process leads to a product with 
a new TRL. Therefore we can summarise the different TRLs into three uses: 
1. The TRL the supplier promises when you buy a product from them and 
2. The TRL that you experience when using the product. 
3. The TRL of the process of manufacturing the product. 
 
 
3.2.2 “Emerging technologies” 
AM is not only an emerging technology that has the potential to replace many conventional 
manufacturing processes, but also an enabling technology allowing new business models, new 
products and new supply chains to emerge [8].  Emerging technologies are technological 
advances that are currently in development. They have the potential to replace current 
technology in the workplace and are within the development phase of their technological life 
cycle. Emerging products are becoming more complex and require multiple capabilities within 
the company. Without the certain manufacturing capabilities, companies are vulnerable to 
market shift [9]. This is just some characteristics    of emerging 
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technologies. Many others exist; the researcher found that these are the ones relevant to this 
study. 
 
3.2.3 “Readiness” and “maturity” 
When companies want to implement an emerging technology, it is important to consider 
whether they are ready to implement it. “Readiness” is a measure of the suitability of a 
technology or products for use within a  larger system  in  a  particular context [10]. Smith 
[10] recognised that the terms readiness and maturity are sometimes used interchangeably 
and argues that a mature product can have a greater level of readiness for a specific use or 
system than one with lower maturity. The individual readiness components and their 
contributions to the system or product make it difficult to determine the overall readiness of 
the technology and also the overall risk assessment [11]. This statement led to many articles 
on Technology Readiness Levels in general. 
 
3.3 Technology Readiness (TRL) 
The concept of “technology readiness levels” (TRLs) was first introduced by the National 
Aeronautics and Space Administration (NASA), in 1970 [5]. TRLs were initially introduced as a 
concept for an independent, programmatic figure of merit (FOM) to allow for effective 
assessment and communication of maturity of new technologies. In 1995, the TRL scale was 
strengthened by the articulation of definitions of each level [12]. Since then, TRLs have proven 
to be effective in communicating the status of new technologies within organizations. 
 
Figure 2: Technology Readiness Level (TRL) [12] 
 
TRLs defines the gap between the technology’s maturity and the maturity needed for it to be 
successful [13].The basic model of TRLs is shown in Figure 2. 
In South Africa, TRLs have been used within AM by the CSIR [7]. NASA used TRL to assess the 
maturity of a particular technology and a scale to compare technologies [14]. NASA originally 
created TRL to mature to TRL 6 which states that only at level 6 can a mission assume 
responsibility [15]. In 1999, the Department of Defence (DoD) embraced the TRL concept and 
expanded it to reach TRL 7 before the technology can be included in their program [14]. 
 
These differences caused researchers [14] to state that TRL: 
1. Does not demonstrate the difficulty of integrating technologies into an operational 
system [13], [16], [10], [11] 
2. Does not include guidance towards uncertainty within maturity movement of TRL 
[15], [16], [10], [17] 
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3. Shows no alternatives to analysing alternative TRLs [13], [16], [10] 
 
When TRLs are now drawn from their individual level of technology to the system context, 
more concerns arise between the interaction of the multiple technologies [14]. Different views 
on how to integrate individual TRLs within a project or system has been explained [14], [18], 
[19]. The experts mentioned, explain that an Integration Readiness Level (IRL) can be used to 
determine the relationship of technologies within a system and then using the IRL to set-up 
the System Readiness Level (SRL). 
 
The concerns of Sauser et al.[14] and Graettinger [20] stated that technology must be 
integrated within a system. Although the SRL is considered in literature as an indicator of 
system readiness it does not address all the indicators required for CRI. Therefore, addressing 
the concerns of Sauser et al.[14] and Graettinger [20] we will attempt to draw the individual 
level of technology to a process context. The technologies will be investigated within a process 
context Graettinger [20] to examine the processes to manufacture a product. 
 
Several literature articles [5], [12], [13], [15], [16], [10], [11], [17], [20]–[25] talk about 
technology readiness without the process chain and others [7], [26]–[29] about the process 
chain and process readiness without the technologies. A gap within this research is that the 
two differing views are not merging. In this research, the fundamental technologies meet the 
process chain and that is why we can argue that the lowest TRL is what we are interested in. 
The reason being that the weakest technology (lowest TRL) in the process chain is most likely 
to have the most adverse effect on the entire process chain. If one technology fails, the entire 
chain will fail. 
 
The TRLs provide a good framework for gauging technology readiness; they are insufficient to 
gauge commercial readiness, since other, non-technological aspects also determine 
commercial viability. This then provide the motivation for the development of a CRI 
framework which links back to but extends the TRL framework. A viable way of setting this up 
is to determine the future or to-be TRLs of the technologies. This is then referred to as the 
goals that have to be obtained in order to achieve the to-be state. 
 
3.4 Commercial Readiness Index (CRI) 
The CRI framework developed by the Australian Renewable Energy Agency (ARENA) aims to 
complement the TRLs by assessing the commercial maturity of technologies across six 
indicators [4]. 
The CRI determines the commercial ranking of the project, and the TRL index is a tool used 
for benchmarking the progress and development of specific technologies through the 
development chain [24]. 
 
The CRI begins once the technology is at a stage where there is proof that is feasible in the 
field [3]. This is at TRL 2. The CRI ranges until the technology is commercially deployed, Figure 
3. ARENA [3] argues that in order to improve commercial readiness of a technology,   it needs 
to progress along certain commercial indicators. 
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Figure 3: TRL and CRI [3] 
 
3.4.1 Commercial Readiness indicators 
 
Companies can determine new technologies’ attractiveness by evaluating their technical   and 
economic viability, market potential and value capture [30]. The financial overheads for 
running machines and buying feedstock are potential barriers to the commercialization of AM 
[8]. Accelerators in commercialization are organizational support, market proficiency and 
organizational-integration [26]. “Maturity” is encapsulated within the notion of “readiness” 
[31]. They are used interchangeably. ARENA [3] has identified indicators to reflect on the 
commercialization process of their industry. The indicators were drawn from experience, 
consulting with stakeholders and reviewing literature. 
 
From the literature it is evident that commercial readiness indicators should include 
stakeholders [32], technical viability [30], market opportunities and proficiency [26],    [28], 
[30], [33], economic viability and value capture [30], [34], organizational support [26] and 
strong R&D efforts [35]. The ARENA [3] CRI framework includes all the above indicators with 
descriptions of each, tailored for application for renewable energy projects. These indicators 
are Regulatory Environment, Stakeholder Acceptance, Technical Performance, Financial 
Performance – Cost, Financial Proposition – Revenue, Market Opportunities, Industry Supply 
Chain and Skills, and Company Maturity. 
 
Each indicator has a Level 1-6 maturity. This means that they are further described based   on 
different level of maturity. Level 1 being the least mature for that specific indicator and Level 
6 being classified as the highest maturity for that indicator. ARENA makes use of a Status 
Summary, described by the indicators, to evaluate at which level of business the project is. 
 
In the present work, the CRI framework developed by ARENA is used as a basis for the 
development of a customised CRI indicators and framework for assessing the commercial 
readiness of AM technologies. 
 
The TRLs can be averaged and then transferred to the corresponding CRI levels of Hypothetical 
Commercial Proposition, Commercial Trial, Commercial Scale up, Multiple Commercial applications, 
Market Competition driving widespread deployment and “Bankable” Grade Asset Class. 
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4. FINDINGS 
 
4.1 Definition of CRI Indicators for AM 
The CRI indicators were transformed from the renewable energy case study to the medical AM 
case -study. Seventeen experts in the industry were interviewed and their combining opinion 
on each indicator was documented. The Indicator descriptions are summarized in Table 1. 
 
 
Table 1: CRI level indicators 
 
Level CRI indicators 
Regulatory Environment 
6 Regulatory and planning process documented and defined with ongoing process of 
review and refinement. To have an internally flexible robustness to change to 
conform to. Investment markets see company policy settings long term, robust and 
proven. 
5 Regulatory, planning and permitting standards conformed to and accredited. 
4 Key findings published on planning, permitting and regulatory challenges based on 
actual evidence. Quality management strategy agreed for accreditation. 
3 Manufacturing quality checks and standards are in place. Process development 
address key barriers in order to gain certification. 
2 Key regulatory barriers emerge and require project specific consideration. 
Reference model with set of rules are referred to when decisions are made. 
1 Quality checks and operations are developed to meet specific standards.  Operators 
are being trained to perform to specified standards. Regulatory body has not yet 
approved operations. 
Stakeholder Acceptance 
6 Processes for change are in place to ensure robustness. 
5 Stakeholders transparently represented in all aspects of the business. IP risk 
mitigated. Stakeholders would like to see the full clinical benefits AM can bring - 
shorter theatre and recovery time. 
4 Evidence and experience is available to inform stakeholders increasing their 
acceptance. Market dictates policy settings and consumerism drives thinking. 
Stakeholder networks based on trust result in funding. 
3 Systematic process to manage stakeholders' input. A plan to mitigate risks is in 
place. Technology features are publically explained to end users in order to develop 
market understanding of benefits. 
2 Stakeholder support is on a case-by-case basis with technology developer skills a 
critical success factor. Processes are based on best practice principles and 
documented accordingly. Intellectual Property (IP) risk identified and mitigation 
policy in place. 
1 Stakeholder support is limited to collaborative research group. A plan to mitigate 
risks is in progress. 
Clinical Performance 
6 The product as well as the procedure is internationally recognised for a high 
number of successful cases. 
5 Regular credit from peer reviewers. Standard operating procedure is in place.  
One component associated with procedure decreasing the risk. 
4 The research and proven studies must be published in several international journals 
and presented at medical conferences. Procedure is faster than the typical 
procedures. Patient has a high chance of survival. 
3 The research and proven studies must be published in several journals. Several 
successful procedures have been done. Product is available for purchase. 
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2 The procedure is done in a proven clinical study operating theatre. Many 
components associated with procedure and product, several components are used 
within complex procedure. Products are modified during procedure. High 
customisation of product is needed. 
1 Clinical performance is in progress. Patient has a chance of survival. The reaction 
of the body to the product is unproven. 
Technical Performance 
6 Secondary markets exist to access externally verified performance information  for 
routine due diligence. Performance review and warranty credit rating transparent. 
5 Multiple data sets discoverable on our commercial products operating in a rang  of 
applications. Medical regulation approval. Proof of what you promise for example a 
certificate on the wall. 
4 Performance yield, efficiency vs. forecasts published and key drivers understood. 
Performance evaluation methodology and warranties becoming standard. High 
confidence in production viability. 
3 Quality standards and accreditations on technical performance proven. Product 
complies with customer expectation. Tacit knowledge of production process ensures 
100% capability. Production becomes viable for venture capitalists. International 
evidence key in investment. Finite Element Analysis (FEA) procedure in place. The 
design criteria lead to an effective and sustainable product with low risk. 
2 Production performance forecasts based on simulation models from research & 
development or pilot scale demonstration. International performance used to 
support investment case. 
1 Standards and accreditation are in progress. Machine performance improvement in 
progress. Production data based on prototypes and forecasts with little or no prior 
data to substantiate. Design does not yet lead to a sustainable product. 
Financial Proposition -Costs 
6 
Cost detail indices widely published and accepted for multiple similar  
applications. System cost competitive to drive uptake. 
5 The cost model reliably reports the recommended retail price of the product. 
Product price and value proposition clear and attractive. 
4 The cost model is flexible to allow for product variations. Commoditisation of major 
components occurring. Cost drivers are publically understood with roadmaps to 
market competitiveness. 
3 The cost model is verified to accurately forecast products cost for quotations. 
Focus moving towards lowering unit costs and risk. 
2 Key costs based on projections with some actual data available to verify. The cost 
model is being validated to actual accounting data. Supply chain stages' engineering 
costs based on time and materials with high degree of risk loading. 
1 Cost model is being developed to determine the risk management strategy for the 
feasible region in which we are operating. Cost data based on projections and 
forecasts with some data to substantiate. 
Financial Proposition - Revenue 
6 Transparent benchmarking is evident. Revenue sustainably robust through market 
variations. 
5 Revenue projections based on proven forecasts and accepted commercial data. 
Product price sustainable to ensure market share increases. 
4 Revenue projections backed by commercial data. Price gaps understood and 
roadmaps in place to address. Revenues generating sufficient cash flow to service 
debt and equity expectations. 
3 Revenue sufficient to break-even production costs. Overheads subsidised by 
research and development funding. Revenue projections being tested in commercial 
context by investors. Tax subsidies applied for. 
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2 Some revenue is generated and cash is received. Revenue projections highly 
discounted by investors. 
1 
Revenue data based on projections and forecasts with little data to substantiate. 
Funding 
6 
Stock exchange generated public funding. 
5 
Recurring funding from investors based on underlying value of proposed asset. 
4 Investors comfortable to secure debt based on financial ratio such as recurring 
revenue as a % of operating expenses. 
3 Funding gaps between net present value of revenue and cost benchmarked to 
sector indicators. Capital invested is partially subsidised by research grants. 
2 
Small scale production trials funded through research grants. 
1 
Funding for prototyping established. 
Industry Supply Chain and Skills 
6 Multiple alternatives with proven capability. Product and service is key 
differentiation selection factor. Process flexible to react timeously to change in 
trends. 
5 The supply chain is set up for future development. Specialisation occurring along 
supply chain with standards defined and supplier performance externally 
benchmarked. Service level agreements are in place. 
4 Key skills demonstrate batch process efficiency with replicable results. Industry 
supply chain and market channels proven to deliver. Time-to-build measured as a 
key driver of efficiency. 
3 The supply chain is set up through several businesses to spread risk. Limited 
availability of key components and manufacturing, operational and maintenance 
skills. Business plan to move from start-up to scale-up approved by stakeholders. 
2 Most supply chain stakeholders conform and are willing to participate. The 
manufacturing process policy is in place as engineer-to-order. SCOR reference 
framework is used in collaboration with best practices. 
1 Key elements in supply chain identified and from specialist source. Service level 
agreements are being negotiated, often under technology proponent's 
specifications. 
Market Opportunities 
6 The company has a large market share. 
5 Market driving the investment process. Management policy robust to external 
factors. 
4 Market demand primary driver of the investment case with some concessional 
policy support. Market size widely available and verified by third parties 
competitors. Target segment customers are key stakeholders in the investment 
decision process. 
3 There must be proof of an irrevocable offer to purchase. Active advertising and 
marketing system to generate leads with follow up action plan. Detailed market 
research to understand the size, interest and readiness of the market available. 
2 Commercial trial has identified the target market segment proving to investors 
that the technology is clinically reliably. Market research has been done to enable 
proponents to estimate the market size locally and internationally. 
1 Some opportunities available. Expert opinion confirms commercial evidence for 
investment case based on market size and early channel to market. 
Company Maturity (CRPM Medical Pty Ltd.) 
6 The company can be listed as a public company. Company is resilient to react to 
external factors. 
5 Company lead by governance policy to ensure shareholder value. Company KPIs 
are aligned with shareholder value and met. 
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4 A recognised quality management system imbeds trust with stakeholders. 
Company structure is in place and systems are automated to support perceived 
shareholder value. The company is the main driver of the technology. 
3 Industry stakeholders in place and strongly represent the sector. Industry sector 
still driven by technology proponents within research institutes. The company has 
started developing a corporate governance system. 
2 Internal management systems are being developed and the company now has 
several decision makers with a unanimous goal. Industry stakeholders are weaker 
than research institutes. 
1 Company structure is in progress. Several high level responsibilities resides in one 
person. Manufacturing and technology capability is being transferred from research 
institutes to industry stakeholders. 
 
It will be noted that a ninth indicator called Clinical Performance and a tenth indicator 
Funding was added to the list. This is because medical AM products critically depend on clinical 
performance measures in order to be commercially ready and funding that was previously 
included within Revenue now forms an independent indicator. 
 
4.2 Definition of CRI Framework for AM 
The Status Summary Levels previously mentioned are described in Table 2. 
 
Table 2: Status Summary Levels 
 
Level Status Summary 
6 Bankable Grade Asset 
Class 
Considered as a "Bankable” grade asset class with known 
standards and performance expectations. Market and 
technology risks not driving investment decisions. 
5 Market Competition 
Driving Widespread 
Deployment 
Competition emerging across all areas of supply chain. 
Verifiable data on technical and financial performance in 
the public domain. 
4 Multiple commercial 
application 
Becoming evident locally although still subsidised. 
Verifiable data on technical and financial performance in 
the public domain driving interest from variety of debt 
and equity sources however still requiring government 
support. Regulatory challenges are addressed in multiple 
jurisdictions. 
3 Commercial Scale-up Small scale, first of a kind project funded by equity and 
government project support. 
2 Commercial Trial Small scale, first of a kind project funded by equity and 
government project support. Commercial proposition 
backed by evidence of verifiable data typically not in the 
public domain. 
1 Hypothetical Commercial 
Proposition 
Technically ready – commercially untested and 
unproven. Still subsidized by government. 
 
 
Each indicator level is mapped on the Status Summary Matrix, in Figure 4. 
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Figure 4: Simplified Status Summary Matrix 
 
 
4.3 Case study to demonstrate the AM CRI framework 
The AM CRI framework is demonstrated by example of medical AM products. 
 
4.3.1        Case Study: Maxillofacial AM manufactured in Ti6Al4V 
The case study is now used to help in understanding the methodology approach used to 
determine the CRI for medical AM products. The indicator levels are assesed according to   an 
as-is and a to-be state. The to-be state is where we want to be in the future and the as- is 
state is our current state. Table 3 shows the results. The as-is and to-be states are indicated 
in red and yellow respectively. 
 
Table 3: Indicator levels - maxillofacial implant 
 
Level CRI indicator - maxillofacial implant 
Regulatory Environment 
6 Make use of automatic software and streamline the technical files. 
5 Limited standards exist for manufacturing and implanting prosthesis into the human 
body. Standards are based on best practices and Standard Operating Procedures 
(SOPs). ISO system is in place and we know the regulatory body. 
Stakeholder Acceptance 
5 Tacit knowledge skills transfer program. Multiple successful case studies can be 
achieved. 
3 Design follows a process. The plan to mitigate risks is in place. Stakeholders are 
sometimes still uncertain. Number of doctors needed unknown if process gets 
commercialized. Many outsourced processes that bring uncertainties. 
Clinical Performance 
5 Hospitals and medical insurance companies use AM implants as the norm and 
medical assurance authorisation codes are developed for custom procedures. 
3 Product has been tested to render acceptable results. 
Technical Performance 
4 Successful ramp up of production to support a portion of SA market. Technical 
performance constant with higher production values. Process monitoring systems 
are in place to log process conditions. 
3 Yearly successful ISO surveillance audits shows that technical performance is 
sound. Production still limited but repeatable. 
Financial Proposition –Costs 
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4 Publish more articles on cost structures. Cost structures should be benchmarked 
with other institutions. ROI is clearly understood if other similar spin-offs needs   to 
be established 
3 Key costs not yet in the public domain. 
Financial Proposition – Revenue 
4 Proof of concept with the investors to see real revenue and market opportunities. 
3 Know where the profit lies, but market size unknown. 
Funding 
4 Private companies are investing into this venture. The manufacturing bureau is 
financially sustainably. 
3 Some of the activities are subsidised through research grants and other  
commercial activities. 
Industry Supply Chain and Skills 
3 Doctor information requirements must be standardised. Procedures from suppliers 
must be adjusted to comply with the AM process. 
2 Product manufacturer typically designing and procuring multiple elements to own 
specification. AM processes streamlined. Technology proponent specification 
given to suppliers. 
Market Opportunities 
4 Product line partnership with sector specific customers. 
1 Market size, locally and internationally not yet estimated. The technology is still 
in the critical stage of being a promising technical solution moving into a 
prospective commercial opportunity. 
Company Maturity 
5 Independent entity concentrating on manufacturing. Constantly engaging 
research institute for continuous improvement. 
2 Support structure in place for small scale production. The company needs to 
mature in terms of commercialization. 
 
Table 3 is then mapped in Figure 5. Using the average calculation [3], the as-is Status Summary 
of this product is at CRI 3 and the to-be Status Summary is as CRI 5. The  difference between 
the as-is and the to-be state is a mechanism to identify actions to be taken by the 
manufacturer to improve the maturity of the indicators. 
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Figure 5: Status Summary Matrix - maxillofacial implant 
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5. RESULTS 
 
Expert opinions are compiled into different maturity levels of each indicator. Subsequently 
these indicators are reiterated with individual experts for their conformation. Results from 
expert opinions provided the different levels of maturity for each indicator. The case study 
on maxillofacial implants was tested against this framework and the CRI reported accordingly. 
CRI determined at status of Commercial Scale-up at CRI 3. 
 
6. CONCLUSION 
 
A commercial readiness index for additive manufacturing technologies is proposed. The 
opinions of seventeen experts were compiled into levels of maturity for each independent 
commercial indicator. Commercial indicators are used to assess the commercial maturity of 
an enterprise’s ability to unlock the potential of emerging technologies. Commercial 
indicators are independent parameters, averaged to a single Commercial Readiness Index. 
 
The CRI framework helped recognise the KPIs within the case study’s manufacturing  process. 
It also helped the expert to understand and learn about the possibilities regarding 
commercialization of a complex product. The CRI framework helped to identify the main 
barriers that need to be addressed to move from the as-is state to the to-be state. 
 
The technology framework will help with the technological uncertainty of the product, and 
show project and process risks associated with the manufacturing of the product. In South 
Africa it can be implemented within research organisations such as  Idea2Product,  LaunchLab 
and Maker Station, among others. This would mean more people embracing AM and enabling 
the average person to become economically active in the AM industry in South Africa. 
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